| |
Gain expert advice on navigating the stakeholder ecosystem—from payers and policymakers to patients and community oncologists. Download the eBook now to drive commercial success and outcomes in cancer care.
+(1).png)
|
|
Today's Big NewsJul 20, 2023 |
| By Eric Sagonowsky Despite the widespread hype surrounding new and powerful obesity medicines, the drugs are still out of reach for many Americans who could benefit. A group of lawmakers is working to change that. |
|
|
|
| Philadelphia, PA |  |
|
|
By James Waldron Despite interest from GSK and high hopes of leading the next generation of influenza A prophylaxis, Vir Biotechnology’s monoclonal antibody has failed its first phase 2 challenge. |
By Conor Hale The miniature heart pump maker Abiomed—which J&J picked up last year for $16.6 billion—accounted for nearly a third of J&J's quarterly medtech gains. |
By Fraiser Kansteiner One of the world’s largest sterile injectables plants has landed in the path of a devastating act of nature. Wednesday, Pfizer said its manufacturing facility in Rocky Mount, North Carolina, suffered damage from a tornado. All of the company's employees are safe and accounted for. |
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more. 
|
|
By Max Bayer Johnson & Johnson's reassessment of its infectious disease and vaccine work does not appear to be over, with the company cutting the number of assets in development in half. The cuts come six months after the overhaul of the two units was first disclosed to staff. |
By James Waldron With Pfizer’s entry in the RSV race soaking up most of the press attention, it’s easy to forget that the Big Pharma has other vaccines in the works. They include a maternal vaccine for group B streptococcus (GBS), which has posted some positive data after a long period of radio silence. |
By Fraiser Kansteiner Sandoz is doubling down on its commitment to Slovenia in its globe-trotting biosimilar growth quest. Its latest move follows a separate $400 million pledge to build a plant in the country. |
By Andrea Park For the quarter, Abbott’s COVID-19 tests brought in just $263 million. Not only does that mark a drop of nearly 90% compared to the $2.3 billion the diagnostics raked in during the same period last year, but it also dampens the company’s overall sales performance, which came in 11.4% lower than last year. |
By Gabrielle Masson Sanofi is paying Recludix Pharma $125 million and offering up more than $1.2 billion in biobucks for a pact that will take aim at multiple immunological and inflammatory indications. |
By Ben Adams Despite the major decline in COVID-19 vaccine sales since the 2022 peak, the infectious disease market is still expected to grow by 5.7% through 2029 with Pfizer, Gilead and GSK all set to be the dominant forces in this market. |
By Andrea Park Once the subject of a $1.2 billion market cap, ViewRay is now scrambling to stay afloat. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
